Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/29/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Donald G. Payan

Wrong Dr. Donald G. Payan?

Chief Scientific Officer and Foun...

Phone: (650) ***-****  HQ Phone
Email: d***@***.com
Rigel Pharmaceuticals , Inc.
1180 Veterans Boulevard
South San Francisco, California 94080
United States

Company Description: Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
  • M.D.
    Stanford University
  • B.S.
    Stanford University
159 Total References
Web References
senior management: Rigel Pharmaceuticals
www.rigel.com, 10 June 2014 [cached]
Donald G. Payan, MD
Donald G. Payan, M.D., one of Rigel's co-founders, has been a member of our Board since July 1996 and was appointed Executive Vice President and President of Discovery and Research in February 2008 . From January 1997 to February 2008, Dr. Payan served as our Executive Vice President and Chief Scientific Officer. Dr. Payan also served as Rigel's Chief Operating Officer from January 1997 to July 1998 and as our President and Chief Executive Officer from July 1996 to January 1997. Prior to Rigel, Dr. Payan was Vice President of AxyS Pharmaceuticals (now Celera), a biopharmaceutical company, and Executive Vice President and Chief Scientific Officer of Khepri Pharmaceuticals, which he founded and subsequently merged with AxyS Pharmaceuticals. Dr. Payan is a former Professor at the University of California, San Francisco and Member of the Howard Hughes Medical Institute. Dr. Payan holds an M.D. and a B.S. from Stanford University and completed his residencies and fellowships at the Massachusetts General Hospital and Harvard Medical School.
Donald G. Payan, ...
www.sec.gov, 4 April 2013 [cached]
Donald G. Payan, M.D.
...
Donald G. Payan, M.D., one of our co-founders, has been a member of our Board since July 1996. In February 2008, Dr. Payan became our Executive Vice President and President of Discovery and Research. Prior to this, he had served as Executive Vice President and Chief Scientific Officer since January 1997. From January 1997 to July 1998, he also served as our Chief Operating Officer. From July 1996 to January 1997, Dr. Payan served as our President and Chief Executive Officer. From December 1995 to May 1996, Dr. Payan was Vice President of AxyS Pharmaceuticals, Inc., a biopharmaceutical company. From September 1992 to December 1995, Dr. Payan was Executive Vice President and Chief Scientific Officer of Khepri Pharmaceuticals, Inc., which he founded and subsequently merged with AxyS Pharmaceuticals. Dr. Payan did his residency training in Medicine at the Massachusetts General Hospital, and is a former Professor at the University of California, San Francisco and member of The Howard Hughes Medical Institute.
...
Donald G. Payan, MD(11)


www.sec.gov, 19 May 2003
[cached]

        Donald G. Payan, MD, age 54, is our co-founder, has been a member of our board of directors since July 1996 and has served as our Executive Vice President and Chief Scientific Officer since January 1997.From January 1997 to July 1998, he also served as our Chief Operating Officer.From July 1996 to January 1997, Dr. Payan served as our President and Chief Executive Officer.From December 1995 to May 1996, Dr. Payan was Vice President of AxyS Pharmaceuticals, Inc., a biopharmaceutical company.From September 1993 to December 1995, Dr. Payan was the founder and Executive Vice President and Chief Scientific Officer of Khepri Pharmaceuticals, Inc., which merged with AxyS Pharmaceuticals.Dr. Payan continues his association with the University of California, San Francisco, which began in 1982, where he is currently an Adjunct Professor of Medicine and Surgery.Dr. Payan holds a BS and an MD from Stanford University with AxyS Pharmaceuticals.

...

        We have an employment agreement with Dr. Payan, our Executive Vice President and Chief Scientific Officer, dated as of January 16, 1997, which was amended in March 2003 and continues indefinitely.Pursuant to the terms of the amended agreement, Dr. Payan is entitled to receive an annualized base salary of $185,000 and was issued 750,000 shares of our common stock.As of January 16, 2000, all such shares were fully vested and not subject to a right of repurchase by us.Either Rigel or Dr. Payan may terminate his employment at any time for any reason.If we terminate Dr. Payan's employment without cause, he will receive a severance payment equal to his annual base salary in effect at the date of termination.

...
As a condition to the Investors' execution of a purchase agreement providing for the Private Placement, certain of our stockholders who are affiliates of Rigel, including Alta, Frazier, James M. Gower, our chief executive officer and chairman of the board, and Donald G. Payan, our executive vice president and chief scientific officer and a director, entered into voting agreements with MPM Capital that require these stockholders to vote all of their shares of common stock in favor of approval Proposals 1, 2, 3, 4, 5 and 6.
...

        We have an employment agreement with Dr. Payan, our Executive Vice President and Chief Scientific Officer, dated as of January 16, 1997, which was amended in March 2003 and continues indefinitely.Pursuant to the terms of the amended agreement, Dr. Payan is entitled to receive an annualized base salary of $185,000 and was issued 750,000 shares of our common stock.As of January 16, 2000, all such shares were fully vested and not subject to a right of repurchase by us.Either Rigel or Dr. Payan may terminate his employment at any time for any reason.If we terminate

70



Dr. Payan's employment without cause, he will receive a severance payment equal to his annual base salary in effect at the date of termination.

Rigel to Host Investor Briefing on December 1, 2004
www.prnewswire.com, 29 Nov 2004 [cached]
Donald G. Payan, M.D., Rigel's Chief Scientific Officer and Executive Vice President, will provide an overview of Rigel's efforts to develop small molecule drug candidates to treat allergic rhinitis, hepatitis C virus (HCV), rheumatoid arthritis and cancer.In addition, Dr. Payan will outline next steps in Rigel's HCV clinical trial program.
...
Dr. Payan is Executive Vice President and Chief Scientific Officer of Rigel Pharmaceuticals.He is one of Rigel's co-founders and a member of the Board of Directors.Dr. Payan has held senior level positions at numerous biotechnology companies, including AxyS Pharmaceuticals, Inc. and Khepri Pharmaceuticals, Inc.He is also an Adjunct Professor of Medicine at the University of California, San Francisco and is Board Certified in allergy and anti-infectives.
board of directors: Rigel Pharmaceuticals
www.rigel.com, 10 June 2014 [cached]
In addition to James Gower and Donald Payan, M.D., Rigel's Board of Directors includes the following members:
Other People with the name "Payan":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304